(OATs) were addressed in detail. E.g., OATPs mediate transport of contrast agents used for magnetic resonance imaging of the liver or transport agents used for hepatobiliary scintigraphy, while OATs transport substances used in renography. In addition, the multidrug resistance transporter 1 (MDR1 or P-gp), which is the most important gate keeper in epithelial or endothelial barriers for preventing the entry of potentially harmful substances into organs was addressed. Novel substrates suitable for positron emission tomography (PET) allow studying such transporters at the blood brain barrier or while mediating uptake of drugs into hepatocytes and, importantly, PET tracers allow now also renography. Finally, quantitative data on transporter expression in human organs allow the development of improved physiologically based pharmacokinetic (PBPK) models for drug disposition. Hence, the combined effort using novel substrates for in vivo visualization of transporters and quantification of transporters will lead to a deeper understanding of transporter function in disease and allow development of novel PBPK models for disease states.
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Introduction
Transporters are key elements controlling many homeostatic processes in the body and they are essential elements in the processes involved in drug disposition. In addition, transporters are now also recognized to be very important in understanding the molecular basis of diagnostic tools, as they mediate e.g. the transport of endogenous (Stieger et al., 2012; Hoekstra et al., 2013) or exogenous (Van Beers et al., 2012; Pastor et al., 2014) liver function markers.
Against this background, it is important understanding the changes of transporter functions in disease states and to develop new tools for studying individual transporters in vivo. In addition to working with in vitro in model systems, transporter function can be addressed by quantifying the amount of transporters and their post-translational modifications in tissue specimens from patients. To study transporters in vivo, developing substrates, which are specific for a transporter and are amenable for detection by non-invasive procedures is an attractive option. An area, in which a lot of effort is currently being invested is the development of radiolabelled transporter substrates detectable by positron emission tomography (PET). Another important aspect is the development of detailed physiology based pharmacokinetic (PBPK) models allowing to study in vitro the disposition and the potential interaction of drugs with new chemical entities. Such models require accurate knowledge on the protein abundance of transporters and drug metabolizing enzymes in humans.
The aim of this ASPET sponsored symposium was to highlight the role of transporters in classic diagnostic procedures as well as to provide examples of novel probe substrates for transporters.
In addition, data on transporter expression levels in humans in the context of developing in silico models, e.g. for drug disposition were discussed.
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The role of transporters for diagnostic probes (B.S.)
One of the key functions of the liver is bile formation and disturbance of this process may lead to liver disease. Bile salts are major constituents of bile and are amphipathic organic anions (Esteller, 2008) . The clearance of radioactively labeled bile salts from blood plasma has been demonstrated to be reduced in patients with liver disease (LaRusso et al., 1975) , suggesting that bile salts could be used a liver function markers. Today, the relevant transporters for hepatocellular bile salt transport have been cloned and functionally characterized (Meier and Stieger, 2002; Stieger, 2011; Hagenbuch and Stieger, 2013) : the sodium taurocholate cotransporting polypeptide NTCP, the organic anion transporting polypeptides (OATPs) and the bile salt export pump BSEP are key bile salt transporters in hepatocytes under normal physiologic conditions.
OATPs constitute a family of truly multispecific transporters and mediate in addition to bile acids the transport of other endogenous substrates like steroid metabolites (Hagenbuch and Stieger, 2013) (Stieger and Hagenbuch, 2014) , of a wide variety of drugs (Hagenbuch and Stieger, 2013; Stieger and Hagenbuch, 2014) and endogenous (e.g. bilirubin and its conjugates) and exogenous liver function markers, such as bromosulfophthalein (BSP) or indocyanine green (ICG) (Stieger et al., 2012; Van Beers et al., 2012) . The first OATP cloned was identified by using an expression cloning approach from rat liver mRNA with the liver function marker BSP as lead substrate (Jacquemin et al., 1994) and this OATP is strongly inhibited by ICG (KullakUblick et al., 1994) . All OATPs expressed in human liver mediate in vitro transport of BSP (Kullak-Ublick et al., 2001 ). While BSP is not in clinical use anymore, ICG is used in clinics as an exogenous liver function marker (Sakka, 2007; Hoekstra et al., 2013) . Interestingly, only OATP1B3, but not OATP1B1 and OATP2B1 mediate in vitro transport of ICG (de Graaf et al., This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on September 23, 2014 as DOI: 10.1124 at ASPET Journals on April 13, 2017 dmd.aspetjournals.org Downloaded from DMD #59873 7 2011). Of note, the latter study also demonstrated NTCP-mediated ICG transport. The in vivo relevance of these findings on ICG is supported by the positive association of ICG accumulation in hepatocellular carcinomas with the expression of NTCP and OATP1B3 (Ishizawa et al., 2014) . ICG is excreted into bile via the multidrug resistance associated transporter 2 (MRP2) (Sathirakul et al., 1993) . Plasma bilirubin is routinely determined in the workup of patients with liver disease. Bilirubin and its conjugates can therefore be considered as endogenous liver function markers. They are transported by OATP1B1 and OATP1B3 into hepatocytes and by MRP2 into bile or in disease states by MRP3 back into the sinusoids (Keppler, 2011; Stieger et al., 2012) . These above examples demonstrate that transport systems for organic anions play a major role in handling of endogenous and exogenous liver function markers. Organic anion transporters are therefore very important as mediators of cellular uptake of diagnostic probes, which are anions.
Magnetic resonance imaging (MRI) or liver scintigraphy are frequently used for diagnosing liver disease e.g. for focal lesions. Diagnostic probes used in these procedures are mostly negatively charged (Hoekstra et al., 2013; Pastor et al., 2014) . Hence, MRI agents (Pastor et al., 2014 ) and mebrofenin (de Graaf et al., 2011) have been demonstrated to be substrates of organic anion transporters such as OATPs or MRP2. Mebrofenin has recently been suggested to be used as a liver function marker for helping to improve the outcome of liver resections (Hoekstra et al., 2013) .
Focal and diffuse liver disease may lead to an alteration of transporter expression (Geier et al., 2007; Pollheimer et al., 2014) in the diseased and in the healthy tissue, which in turn will either influence the plasma clearance or the hepatocellular accumulation of a diagnostic probe.
Parenthetically, expression of transporters for diagnostic probes may be affected by diseases in This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on September 23, 2014 as DOI: 10.1124 at ASPET Journals on April 13, 2017 dmd.aspetjournals.org Downloaded from DMD #59873 8 all organs. Therefore, alterations of results from liver function tests in disease can increasingly be understood at the molecular level. In addition to altered transporter expression in disease states, other confounding factors need to be considered when interpreting data from liver function markers: The impact of interindividual variability of transporter expression will be discussed in the section on the quantification of transporters. In addition, drugs may act as inhibitors of transports systems. For example, rat OATP1A1 and OATP1A4 are suspect to inhibition by the antibiotics rifampicin and rifamycin SV (Fattinger et al., 2000) . In rats, the accumulation of the MRI contrast agent gadobenate dimeglumine (BOPTA) in the liver is inhibited in a dosedependent manner by rifampicin (Daali et al., 2013) . In contrast, in a human study, no evidence was found for a pharmacokinetic interaction between gadoxetic acid clearance and coadministration of erythromycin (Huppertz et al., 2011) .
Next to drug interactions, disease related changes of the local environment of a transporter may affect its transport properties and hence the readout of diagnostic probes. Therefore, a detailed understanding of the transport mechanism(s) of transporters for diagnostic probes is needed.
With respect to OATPs, the transport mechanism is not known in full detail (Hagenbuch and Stieger, 2013; Stieger and Hagenbuch, 2014) , impeding prediction of consequences for diagnostic probes due to alterations of OATP-mediated transport. For example, most, if not all OATPs have more than one substrate binding site, which do not always overlap in substrate specificity (Hagenbuch and Stieger, 2013; Stieger and Hagenbuch, 2014) . This may affect not only the binding of diagnostic probes, but puts limits on the prediction of drug interactions with diagnostic probes. Furthermore, endogenous substances or some drugs may stimulate rather than inhibit the transport activity of individual OATPs (Hagenbuch and Stieger, 2013; Stieger and Hagenbuch, 2014 an acid extracellular pH (Leuthold et al., 2009; Hagenbuch and Stieger, 2013; Stieger and Hagenbuch, 2014) . These issues clearly show that there will be no "on size fits all" concept for the characterization of transport systems with imaging tools. In order to utilize the full potential of transporters in the clinical use of diagnostic probes, considerable efforts to fully understand the mechanisms of transporters as well as the impact of diseases on transporters at the levels of function and expression will be needed.
Nevertheless, first studies demonstrating the use of bile salts as an example for an endogenous imaging marker provide a proof of concept for the feasibility of visualizing transporters involved in bile formation in vivo (Frisch et al., 2012; Jia et al., 2014) . Therefore, when conducting pharmacokinetic or efficacy and toxicity studies, the typical approach has been to assume that the unbound concentration in the tissues can be approximated by the unbound concentration in the plasma. With the emerging knowledge about transporters and their localization in multiple tissues, it is clear that this assumption is no longer valid. For example, as described in the previous section, a drug may be transported into the liver by the sinusoidal OATPs where it may be metabolized or excreted into the bile by one of the canalicular efflux transporters (e.g. BCRP, P-gp or MRP2). Depending on the relative magnitude of the This article has not been copyedited and formatted. The final version may differ from this version. (He et al., 2014) . Similarly, as previously demonstrated by us and others (Sasongko et al., 2005; Hsiao et al., 2008; Eyal et al., 2009; Muzi et al., 2009; Eyal et al., 2010; Bauer et al., 2012; Mullauer et al., 2012; Bankstahl et al., 2013; Ke et al., 2013; Deo et al., 2014) , when a drug is effluxed out of the brain, its concentration in the brain can be much lower than that in the plasma. This disconnect between tissue and plasma drug concentration will be modulated in the presence of a drug-drug interaction (DDI). For example, when P-gp is inhibited at the human blood-brain barrier, the brain concentration of 11 C-verapamil, a P-gp substrate, almost doubles, but the plasma concentration profile of 11 C-verapamil is not affected (Sasongko et al., 2005; Eyal et al., 2010) . involved (e.g. influx or efflux transporters), the clearance via these transporters will be the sum of the clearances via each transporter. However, we note here that clearance via the influx and efflux transporters are not additive.
Quantification of Drug Transporters to
In the above equations, K cat is transport turnover rate, SF is scaling factors, [T] is transporter expression.
While transporter expression in tissues or cells can be quantified using antibodies, because purified standards of the majority of transporters are not available, such quantification is not absolute (e.g. pmol amounts per mg protein) and therefore cannot be used in PBPK model predictions. To address this deficiency our laboratory (and those of others) has begun to utilize LC-MS/MS proteomics and surrogate peptides to quantify transporter protein expression in tissues and cell lines (Li et al., 2009; Shawahna et al., 2011; Uchida et al., 2013; . However, irrespective of the method used to quantify transporter expression, several methodological questions arise when utilizing such data for IVIVE and PBPK model predictions.
These methodological questions are discussed below.
Methodological Issues: First, for IVIVE, the method used for quantification of transporters should ideally measure functional transporters present in the plasma membrane and not those present intracellularly. However, it is widely acknowledged that high throughput methods to purify plasma membranes are currently not available. Therefore, for IVIVE to be successful, the expression of the transporters in plasma membrane vs. total expression in the cell should be similar in vitro (i.e. in cell lines used for IVIVE) and in vivo (i.e. in human tissues). Secondly,
This article has not been copyedited and formatted. The final version may differ from this version. 
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To address the question of whether membrane expression and activity of transporters correlates, we created, using lentiviral shRNA, clones of cells expressing varying levels of BCRP or OATP1B1 expression. Then, we quantified the total membrane expression (by LC-MS/MS) and transporter activity in each clone. We found that the expression was highly correlated with activity (r 2 >0.9). These data suggest that even when transporter expression and activity is high, as in overexpressed cell lines, such cell lines can be used for IVIVE of transporter activity.
Finally, we have addressed a methodological problem specific to LC-MS/MS proteomics.
Briefly, this method is based on LC-MS/MS quantification of unique surrogate peptides liberated after trypsin digestion of the protein. Therefore, as we have stressed before , this method assumes that tryptic digestion of the protein is complete. This assumption can be tested only when the purified protein is available. We were able to test this assumption with purified P-gp. Our assumption of complete digestion of P-gp was found to be correct. We were able to recover the concentration of P-gp in the purified sample using the LC-MS/MS peptide quantification approach (Prasad et al., 2013) . Ideally, if the purified transport protein is available, this assumption should be tested for every transport protein quantified.
Transporter expression in human tissues: Having addressed the above methodological issues, we have utilized LC-MS/MS to quantify the expression of a number of drug transporters and the interindividual variability in their expression in human livers (n=64), kidneys (n=14) and intestines (n=17), using the surrogate peptide approach. In human livers, we have quantified the expression of hepatic OATP1B1, OATP1B3, OATP2B1, P-gp, BCRP and MRP2. Quantification of expression of other transport proteins important in drug transport and hepatic toxicity (e.g.
BSEP, NTCP, MRP3) has been completed (manuscript in preparation). The key findings from our study were: i) the mean ± SD (fold range in parentheses) protein expression (fmol/µg of This article has not been copyedited and formatted. The final version may differ from this version. (7); ii) the transporter expression was found not to be correlated with age (7-70 years) or sex; iii) consistent with literature data, OATP1B1 and BCRP expression correlates with their genotypes (Deo et al., 2012; Prasad et al., 2013; . For example, livers with SLCO1B1
(encoding OATP1B1) haplotypes *14/*14 and *14/*1a (i.e., representing SNPs, c.388A>G, and c.463C>A), had significantly higher (P<0.0001) protein expression than the reference haplotype (*1a/*1a) . Similarly, BCRP expression in livers with the variant C421A allele was significantly lower than that in the wild-type livers (p<0.002) (Prasad et al., 2013) .
Furthermore, we utilized genotype dependent OATP1B1 expression to predict drug disposition of its substrates, repaglinide and rosuvastatin. Based on the genotype-dependent OATP1B1
protein expression data, we predicted (using Simcyp) up to ~40% decrease in mean area under the curve (AUC) of rosuvastatin or repaglinide in those individuals harboring the *14/*14 and *14/*1a variant alleles compared with those harboring the wild-type alleles .
These predictions are in agreement with data observed in vivo (Kalliokoski et al., 2008) and demonstrate the utility of the proteomics approach to predict the genotype-dependent disposition of drugs in the clinic. (Hsiao et al., 2008; Eyal et al., 2009; Muzi et al., 2009; Eyal et al., 2010; Ke et al., 2013; Deo et al., 2014; He et al., 2014) and those of others. Therefore, the accuracy of the above proposed IVIVE method can now be tested.
PET Imaging of ABC Efflux Transporters at the Blood-Brain Barrier in Humans and
Animal Models (O.L.)
Drug delivery to the brain is partly controlled by adenosine triphosphate-binding cassette (ABC)
transporters, such as P-gp, BCRP or MRP4, which are expressed at the luminal membrane of brain capillary endothelial cells (Kalvass et al., 2013) . These transporters are capable of effluxing a multitude of chemically diverse compounds from the endothelial intracellular space into the vascular compartment thereby limiting their brain distribution. Disease-induced changes in transporter expression at the blood-brain barrier (BBB) may lead to changes in drug delivery to the brain causing decreased efficacy or increased central nervous system side effects of drugs.
It has been shown that epileptic seizures cause up-regulation of P-gp in epileptic brain tissue.
This may hinder access of antiepileptic drugs which are P-gp substrates to their target structures in the brain and thereby possibly contribute to drug resistance in epilepsy (transporter hypothesis This article has not been copyedited and formatted. The final version may differ from this version. of drug resistance) ). An up-regulation of P-gp in human epileptic brain tissue has been demonstrated by P-gp immunostaining of surgically removed brain tissue specimens . However, it is currently poorly understood if this P-gp upregulation has functional consequences, i.e. is able to lower regional antiepileptic drug concentrations below therapeutically effective concentrations. Experimental studies in rat models of drug resistant epilepsy have shown that treatment with the potent third-generation P-gp inhibitor tariquidar (Fig. 1A) is able to restore sensitivity to phenobarbital or phenytoin and to enhance drug concentrations in epileptic brain tissue . These findings suggest that inhibition of P-gp or prevention of seizure-induced P-gp up-regulation may present a promising strategy to overcome drug resistance in epilepsy in the clinic. However, the key question which remains to be answered is if this P-gp-mediated resistance mechanism also occurs in humans.
PET is a nuclear imaging method which allows for measuring the function and expression of proteins in vivo by intravenously injecting protein-specific radiotracers and non-invasive measurement of their tissue distribution over time. 
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transported by P-gp among major efflux transporters expressed at the mouse BBB .
A limitation of (R)-[ 11 C]verapamil to study a regional up-regulation of P-gp in the brain is its low brain uptake, which makes it difficult to detect a signal reduction caused by increased P-gp function. We have shown before that pretreatment of rats with tariquidar enhances brain uptake of (R)-[ 11 C]verapamil . We were interested in finding out if modulation of P-gp by tariquidar may make (R)-[ 11 C]verapamil more sensitive to detect regional differences in P-gp function in the brain. For this approach it appears critical that P-gp is only partly inhibited as complete inhibition of P-gp would cause (R)-[ 11 C]verapamil brain distribution to be dependent on passive diffusion and not on P-gp function. We therefore performed a study in rats to identify a tariquidar dose which only partly inhibits P-gp . Rats underwent (R)- We then validated our P-gp imaging protocol in a rat model of regionally heterogeneous cerebral P-gp expression (Bankstahl et al., 2011) . We used rats at 48 hours after pilocarpine-induced status epilepticus (SE), which were shown to exhibit a regional up-regulation of P-gp in the brain, most notably in hippocampal substructures (Bankstahl and Loscher, 2008) . Post-SE and control rats underwent (R)-[ 11 C]verapamil PET scans after administration of either 15 mg/kg tariquidar (which completely inhibits P-gp at the BBB) or 3 mg/kg tariquidar (which corresponds to the ED 50 ). Both in control and post-SE animals regional brain distribution of (R)- 
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clearly reduced uptake in cerebellum was observed in post-SE rats (Bankstahl et al., 2011) (Fig.   1B ). PET data were analyzed with a two-tissue-four rate constant compartment model, which demonstrated that the efflux rate constant of (R)-[ 11 C]verapamil from brain (k 2 ) was significantly increased in certain brain regions of post-SE versus control rats (cerebellum, thalamus, hippocampus). In the same brain regions where k 2 was increased P-gp immunoreactivity was also found to be increased (Fig. 1C) , suggesting that our PET protocol was capable of measuring regionally increased P-gp function in the rat brain.
We then translated this imaging protocol to healthy human volunteers, who underwent (R)- brain distribution at plasma concentrations >1000 ng/mL, suggesting that P-gp was completely inhibited at the human BBB . When comparing concentration-response curves of tariquidar in humans and rats, it was noted that half-maximum effect concentrations (EC 50 ) of tariquidar to enhance brain uptake of (R)-[ 11 C]verapamil were similar (EC 50 human:
561±24 ng/mL, rat: 544±32 ng/mL). However, the maximum effect of tariquidar was larger in rats than in humans, with a 11-fold increase in (R)-[ 11 C]verapamil brain distribution over baseline scans (without tariquidar administration) observed in rats and a 2.7-fold increase observed in humans .
Our imaging protocol was used at the University of Manchester (UK) and the University College London (UK) within the EU project EURIPIDES in a study in drug resistant temporal lobe epilepsy patients (Feldmann et al., 2013) . Patients and control subjects underwent (R)- (Feldmann et al., 2013) . This effect was not caused by differences in tariquidar plasma concentrations between the two groups (Feldmann et al., 2013) and suggested that P-gp expression was higher in the hippocampus of drug resistant patients as compared with control subjects. Five patients underwent epilepsy surgery, which allowed for correlation of PET results indicated high P-gp expression (Feldmann et al., 2013) . This study provided first in vivo evidence for regionally increased P-gp function in temporal lobe of drug resistant epilepsy patients and suggested that (R)-[ 11 C]verapamil PET may become a useful imaging biomarker in epilepsy.
As alternative to (R)-[ 11 C]verapamil for measurement of P-gp function at the BBB, we developed [ 11 C]tariquidar as a potential radiotracer to measure P-gp density at the BBB (Bauer et al., 2010) .
In vitro autoradiography showed higher binding of [ 11 C]tariquidar in brain slices of FVB wildtype mice as compared with Mdr1a/b (-/-) , Bcrp1 (-/-) and Mdr1a/b (-/-) Bcrp1 (-/-) (-/-) and Bcrp1 (-/-) mice and substantially higher brain uptake in (-/-) mice (14.5-fold higher than wild-type), which suggested that [ 11 C]tariquidar behaves as a dual P-gp/Bcrp substrate at the murine BBB . When mice were pretreated with unlabeled tariquidar (15 mg/kg), brain uptake of [ 11 C]tariquidar was low in animals expressing Bcrp (wild-type and Mdr1a/b (-/-) ) and high in animals lacking Bcrp (Bcrp1 (-/-) and Mdr1a/b (-/-) Bcrp1 (-/-) ), which suggested that [ 11 C]tariquidar is only transported by Bcrp at therapeutic plasma concentrations . In vitro uptake experiments with [ 3 H]tariquidar in cell lines overexpressing murine P-gp (Mdr1a) or Bcrp supported the assumption that saturation of P-gp transport of tariquidar is reached at lower concentrations than saturation of Bcrp transport .
We attempted to exploit the observed concentration dependence of tariquidar transport by P-gp to visualize Bcrp function at the murine BBB, which is of interest as recent quantitative proteomics data suggest that BCRP is the most highly expressed ABC transporter at the human BBB . We could show that [ 11 C]tariquidar brain distribution in Mdr1a/b (-/-) mice increased dose-dependently when animals were pretreated with increasing doses of the Bcrp inhibitor Ko143 (Wanek et al., 2012) . We then pretreated FVB wild-type mice with a dose of tariquidar (8 mg/kg) which completely inhibits P-gp and subjected these animals to [ 11 C]tariquidar PET scans after administration of different doses of Ko143. This resulted again in a Ko143 dose-dependent increase in [ 11 C]tariquidar brain uptake, which suggested that our PET protocol can be used to visualize Bcrp function at the murine BBB (Wanek et al., 2012) .
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 2A) . In a previous study in healthy human volunteers we observed a pronounced rise in brain concentration-time curves of (R)-[ 11 C]verapamil (+74%) in response to an infusion of unlabeled tariquidar administered during the (R)-[ 11 C]verapamil PET scan (Fig. 2B ).
This was attributed to inhibition of P-gp at the BBB by tariquidar and influx of unmetabolized 
Tc-L,L-EC, Figure 3A ) (Taylor, 2014). 99m Tc-DTPA is considered as a glomerular filtration agent because it is freely filtered by the glomerulus due to its low plasma protein binding of ~4% and it is neither secreted nor reabsorbed (Klopper et al., 1972) . Thus, the renal excretion efficiency of 99m TC-DTPA is considered as ~20%, equal to the rate at which it is filtered.
99m Tc-L,L-EC are considered as tubular agents because they are cleared almost exclusively by tubular secretion (Eshima and Taylor, 1992; Van Nerom et al., 1993) . The plasma protein binding of 99m
Tc-MAG3 was found to be ~90% and is not filtered by glomerulus or reabsorbed (Bubeck et al., 1990) . Similarly, the plasma protein-
Tc-L,L-EC was found to be ~30% (Van Nerom et al., 1993) . Figure 3A ) respectively (Eshima and Taylor, 1992; Van Nerom et al., 1993) . Tc-L,L-EC enables them to provide better quality images and, thus, are preferred radiopharmaceuticals for renography (Taylor, 2014) . In addition, tubular agents are best suited to evaluate patients with impaired tubular function. Tc-MAG3 is extracted from the plasma present in the peritubular capillaries into the tubular cells via the basolateral membrane governed by the organic anion transporter (OAT) system expressed in the proximal convoluted tubules, e.g. OAT1 and OAT3 (Shikano et al., 2004; Takahara et al., 2013) . Results from a recent clinical study suggested a larger contribution of Tc-MAG3 renal uptake and excretion. Although, the carbonylglycine (-CO-NH-CH 2 -COOH) moiety is generally believed to be essential for an efficacious fit with the receptor proteins of the OAT system according to Despopoulos' theory (Despopoulos, 1965) , in the case of cylindrical geometry around the subject, which allows acquisition of imaging data with high temporal and spatial resolution. In addition, PET provides substantially superior quantitative data and also better structural information due to high sensitivity, spatial resolution, and signal-tonoise ratios (Townsend, 2008) . For example, spatial resolutions of a clinical PET camera and a clinical SPECT camera are 4-6 mm and about 10 mm, respectively.
In this regard, we recently reported a fluorine-18 (half-life -110 min) labeled hippurate analog, Figure 3B ) as a potential renal tubular PET agent . 18 F-PFH is a PET analog of 131 I-OIH ( Figure 3B Tc-MAG3 renography . A key advantage of PET renography is that it provides temporal tomographic and slice-specific images of renal parenchyma and quantitative data without additional studies. For example, PET images shown in figure 4 could be used as an alternative to renal cortical scintigraphy. Thus, we anticipate that by using PET, the clinical value of renography could be significantly increased. Figure 3B ), which can be produced by a single-step reaction (Pathuri et al., 2012 Sprague Dawley rats revealed a rapid clearance of 18 F-CNPFH primarily through the renalurinary pathway but to a minor extent also through the hepatobiliary pathway. The unexpected hepatobiliary elimination is adding undesirable background signal in the PET images and also could limit its use when the renal function is low. To our knowledge, 18 F-PFH and 18 F-CNPFH are the only two PET renal tubular agents reported so far in the literature that are suitable for renography. Currently, we are evaluating new renal agents based on a generator-produced PET radionuclide, gallium-68 (half-life -68 min). These agents can be prepared in a kit form, which allows them to be distributed by the traditional nuclear pharmacies in a fashion similar to the Tc99m radiopharmaceuticals.
In conclusion, our results obtained so far collectively indicate 18 F-PFH as a promising lead PET renal tubular agent.
18
F-PFH could be an ideal radiopharmaceutical for PET renography since it combines both desirable biological properties of hippurate and nuclear properties of fluorine-18.
The real value of using PET for renography will only be known when appropriate clinical studies are conducted in patients with renal disorders.
Summary
The role of transport systems is now well established in diagnosing diseases with endogenous and exogenous diagnostic markers. The development and the application of novel probes, especially for imaging is rapidly progressing and opens the possibility for studying transport processes in vivo. In conjunction, rapid progress in quantifying the amount of individual transporters will lead to the development of better PBPK models. While there are now many new opportunities for research at hands, clearly more work is needed to understand the mechanistic This article has not been copyedited and formatted. The final version may differ from this version. 
